Milestone Scientific Features CompuFlo® Epidural System at Euroanaesthesia 2018

News & Press
June 5, 2018 7:02 am

Multiple abstracts presented at scientific poster session

LIVINGSTON, N.J., June 05, 2018 — Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today reported on interest generated in the CompuFlo® Epidural System at Euroanaesthesia 2018, the European Anaesthesiology Congress, which was held in Copenhagen from June 2-4, 2018. In addition, three abstracts were presented during a scientific poster session highlighting the instrument’s ability to objectively identify the epidural space in real time.

Euroanaesthesia is Europe’s largest annual event showcasing the latest and the most relevant knowledge with medical experts active in the field of anesthesia, perioperative medicine, intensive care, emergency medicine and pain treatment. This international event gathers thousands of delegates and exhibitors from over 80 countries with upwards of six thousand delegates from around the world.

Sharon Smith, Executive Vice President of Global Sales and Marketing of Milestone Scientific, commented, “The CompuFlo® Epidural System was well received at Euroanaesthesia 2018 with very positive feedback from a number of global distributors, as well as key opinion leaders. We look forward to following up on the leads from this event as we accelerate our sales and marketing activities in Europe and other markets around the world.”

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone’s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website:

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2017. The forward looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Tel: 212-671-1020

Primary Logo